Related Experiment Video
Updated: Aug 23, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Small cell lung cancer: state of the art and future perspectives
Roger Stupp1, Christian Monnerat, Andrew T Turrisi
1Multidisciplinary Oncology Center, University Hospital CHUV, 46, Rue du Bugnon, 1011 Lausanne, Switzerland. roger.stupp@chuv.hospvd.ch
Abstract:
Small cell lung cancer accounts for less than 20% of all lung cancer. The management of this distinct tumor entity differs from the more common non-small cell lung cancer. Primary prevention of smoking exposure remains the most important public health measure. Although small cell lung is an exquisitely chemosensitive disease it remains ultimately fatal for the great majority of patients. Combination chemotherapy regimens have improved response rate and survival of the last three decades. The combination of cisplatin and etoposide has been considered the standard therapy for over a decade. More intensive triplet combination chemotherapy and high-dose chemotherapy have shown improved response rates and survival. Early concomitant and accelerated radiotherapy improves survival in limited stage disease. This review summarizes the current state of the art and future perspectives in detection, staging and standard therapy of small cell lung cancer. Particular emphasis is given to the importance of concomitant and accelerated radiotherapy and consideration of dose-intensive combination chemotherapy regimens.
Insights
Small cell lung cancer (SCLC) is aggressive but responds to chemotherapy. Advanced treatment strategies, including intensive chemotherapy and radiotherapy, are improving survival rates for this challenging cancer.
Area of Science:
- Oncology
- Pulmonology
- Cancer Research
Background:
- Small cell lung cancer (SCLC) constitutes less than 20% of all lung cancer cases.
- SCLC management differs significantly from non-small cell lung cancer (NSCLC).
- Smoking cessation is the primary preventive measure against lung cancer.
Purpose of the Study:
- To review the current state of SCLC detection, staging, and therapy.
- To highlight future perspectives in SCLC management.
- To emphasize the role of radiotherapy and intensive chemotherapy.
Main Methods:
- Literature review of current SCLC treatment modalities.
- Analysis of chemotherapy regimens and radiotherapy protocols.
- Synthesis of data on response rates and survival outcomes.
Main Results:
- Combination chemotherapy, particularly cisplatin and etoposide, has been a standard for over a decade.
- More intensive triplet chemotherapy and high-dose regimens show improved response rates and survival.
- Early concomitant and accelerated radiotherapy enhances survival in limited-stage SCLC.
Conclusions:
- SCLC remains a highly fatal disease despite chemosensitivity.
- Dose-intensive chemotherapy regimens and accelerated radiotherapy are crucial for improving outcomes.
- Continued research into SCLC detection, staging, and treatment is essential.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:21Cancer Survival Analysis
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...